Skip to content
Speaking on a recent Endpoints News panel, Nkarta CEO Paul Hastings discussed the impact of regulatory uncertainty and federal funding cuts on the investment […]
Nkarta’s Hastings discusses environment for biotech funding in Endpoints panel Read More »
America has long been the global leader in rare disease drug development but this leadership is at risk unless Congress protects key incentives In
U.S. leadership in rare disease drugs at risk, BIO expert tells Orphan Drug Congress Read More »
The May 1 reintroduction of two bills designed to strengthen the certainty of U.S. patents earned praise from the Biotechnology Innovation Organization (BIO). The
BIO applauds reintroduction of two bills aimed at patent reform Read More »
Safeguarding human health during clinical research is critically important, but biotechnology has shown that this does not always have to mean using animals to
BIO report outlines use of NAMs to reduce animal testing Read More »
“Data makes you credible; stories make you memorable,” began Amy Niles, Chief Mission Officer of the PAN Foundation, during the Biotechnology Innovation Organization’s (BIO)
Show Me the Evidence: Data to Understand and Break Down Patient Access Barriers! Read More »
Given the importance of intellectual property for biotech, the Biotechnology Innovation Organization (BIO) remains vigilant in ensuring IP is protected. In recognition of World
BIO IP expert reviews the current policy landscape Read More »
April 17 is World Hemophilia Day, and in commemoration, Bio.News sat down to talk with the National Bleeding Disorders Foundation (NBDF) about the importance
World Hemophilia Day: Raising awareness of the need for a cure Read More »
A trade war will harm American growers and the biotech firms who help them increase productivity, according to the Biotechnology Innovation Organization (BIO). President
Tariffs hurt growers and ag biotech, BIO says Read More »
Maintaining biotechnology superiority is essential to the U.S. economy and national security, and it must be supported with strategic federal funding that leans into
Congressional commission urges support in U.S.-China competition for biotech dominance Read More »
We need policy to improve patient access to drugs and address middlemen who increase drug prices, according to participants in a March 27 healthcare
Summit on health care’s future shines light on PBM abuses Read More »
